ISSN: 2148-4902 | E-ISSN: 2536-4553
Helicobacter pylori treatment in Turkey: Current status and rational treatment options [North Clin Istanb]
North Clin Istanb. 2020; 7(1): 87-94 | DOI: 10.14744/nci.2019.62558

Helicobacter pylori treatment in Turkey: Current status and rational treatment options

Mustafa Kaplan1, Alpaslan Tanoglu1, Tolga Duzenli1, Nurdan Tozun2
1Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
2Department of Gastroenterology, Acibadem University, Istanbul, Turkey

According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, many countries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1 gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however, current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence, cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs to revise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori. This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations for rational therapeutic considerations for the eradication of the bacterium. (NCI-2019-0024.R1)

Keywords: Eradication, Helicobacter pylori; proton pump inhibitors; Turkey.

Mustafa Kaplan, Alpaslan Tanoglu, Tolga Duzenli, Nurdan Tozun. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb. 2020; 7(1): 87-94

Corresponding Author: Mustafa Kaplan

Quick Search




LookUs & Online Makale